A retrospective drug utilization evaluation of vancomycin usage in paediatric patients

Journal of Clinical Pharmacy and Therapeutics

Volumn 29, Issue 4, 2004, Pages 359-365

  Hing, W C ^a   Bek, S J ^b   Lin, R T P ^a   Li, S C ^b  

^a KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Drug resistance; Drug utilization review; Glycopeptide; Vancomycin

Indexed keywords

GENTAMICIN; VANCOMYCIN;

ADOLESCENT; ARTICLE; BACTERIAL INFECTION; CHILD; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG USE; DRUG UTILIZATION; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MICROBIOLOGY; NEUTROPENIA; NEWBORN; PAIN; PHLEBITIS; PRACTICE GUIDELINE; PRESCRIPTION; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADOLESCENT; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; DRUG UTILIZATION REVIEW; HUMANS; INFANT; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; RETROSPECTIVE STUDIES; SINGAPORE; TREATMENT OUTCOME; VANCOMYCIN;

EID: 4043159839     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2004.00571.x     Document Type: Article

References (34)

1. Perl TM (1999) The threat of vancomycin resistance. American Journal of Medicine, 106, 26S-37S; discussion 48S-52S.
2. Eliopoulos GM (1997) Vancomycin-resistant enterococci. Mechanism and clinical relevance. Infectious Disease Clinics of North America, 11, 851-865.
3. Schwalbe RS, Stapleton JT, Gilligan PH (1987) Emergence of vancomycin resistance in coagulase-negative staphylococci. New England Journal of Medicine, 316, 927-931.
4. Hermans PE, Wilhelm MP (1987) Vancomycin. Mayo Clinic Proceedings, 62, 901-905.
5. Smith TL, Pearson ML, Wilcox KR et al. (1999) Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. New England Journal of Medicine, 340, 493-501.
6. Belliveau PP, Rothman AL, Maday CE (1996) Limiting vancomycin use to combat vancomycin-resistant Enterococcus faecium. American Journal of Health-System Pharmacy, 53, 1570-1575.
7. Patel R (2003) Clinical impact of vancomycin-resistant enterococci. Journal of Antimicrobial Chemotherapy, 51, 13-21.
8. Kauffman CA (2003) Therapeutic and preventative options for the management of vancomycin-resistant enterococcal infections. Journal of Antimicrobial Chemotherapy, 51, 23-30.
9. Schentag JJ, Hyatt JM, Carr JR, Paladino JA, Birmingham MC, Zimmer GS, Cumbo TJ (1998) Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control. Clinical Infectious Diseases, 26, 1204-1214.
10. Misan GM, Martin ED, Smith ER, Somogyi AA, Bartholomeusz RC, Bochner F (1990) Drug utilization review in a teaching hospital: experience with vancomycin. European Journal of Clinical Pharmacology, 39, 457-461.
11. Jones D, Pulver L, Tai B, Nourse C (2001) Glycopeptide prescribing in an Australian tertiary paediatric hospital. Journal of Paediatrics and Child Health, 37, 342-347.
12. Freeman CD, Quintiliani R, Nightingale CH (1993) Vancomycin therapeutic drug monitoring: is it necessary? Annals of Pharmacotherapy, 27, 594-598.
13. Logsdon BA, Lee KR, Luedtke G, Barrett FF (1997) Evaluation of vancomycin use in a pediatric teaching hospital based on CDC criteria. Infection Control and Hospital Epidemiology, 18, 780-782.
14. Anonymous (1995) Recommendations for preventing the spread of vancomycin resistance. Hospital Infection Control Practices Advisory Committee (HICPAC). Infection Control and Hospital Epidemiology, 16, 105-113.
15. Carson D (1999) Medicines for children. London: RCPCH Publications.
16. Taketomo CK, Hodding JH, Kraus DM (2001) Pediatric dosage handbook. Cleveland: Lexi-Comp Inc, 1001-1003.
17. Rayner C, Ioannides-Demos L, Vujovic O, Spelman D, Spicer W, Tong N, Krum H (1998) Drug use evaluation of vancomycin based on hospital policy and published guidelines. Journal of Pharmacy Practice and Research, 28, 394-399.
18. Misan GM, Martin ED, Smith ER, Somogyi AA, Bartholomeusz RC, Bochner F (1990) Drug utilization review in a teaching hospital: experience with vancomycin. European Journal of Clinical Pharmacology, 39, 457-461.
19. Mehta DK, Martin J, Furniss L, Hargreaves AM, Jordon B, Patterson CA (1998) British National Formulary. Beccles, Suffolk: British Medical Association and the Royal Pharmaceutical Society of Great Britain.
20. Leader WG, Chandler MH, Castiglia M (1995) Pharmacokinetic optimisation of vancomycin therapy. Clinical Pharmacokinetics, 28, 327-342.
21. Rodvold KA, Everert JA, Pryka RD, Kraus DM (1997) Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children. Clinical Pharmacokinetics, 33, 32-51.
22. Miles MV, Li L, Lakkis H, Youngblood J, McGinnis P (1997) Special considerations for monitoring vancomycin concentrations in pediatric patients. Therapeutic Drug Monitoring, 19, 265-270.
23. Goetz MB, Sayers J (1993) Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. Journal of Antimicrobial Chemotherapy, 32, 325-334.
24. Li SC, Ioannides-Demos LL, Spicer WJ, Spelman DW, Tong N, McLean AJ (1992) Prospective audit of an aminoglycoside consultative service in a general hospital. Medical Journal of Australia., 157, 308-311.
25. Li SC, Ioannides-Demos LL, Spicer WJ, Berbatis C, Spelman DW, Tong N, McLean AJ (1989) Prospective audit of aminoglycoside usage in a general hospital with assessments of clinical processes and adverse clinical outcomes. Medical Journal of Australia, 151, 224-232.
26. Nagarajan R (1994) Glycopeptide antibiotics. New York: Dekker M.
27. Arroyo JC, Rosansky SJ, Rosenzweig PN (1986) Red neck syndrome with slow infusion of vancomycin. American Journal of Kidney Diseases, 7, 511.
28. Pau AK, Khakoo R (1985) 'Red-neck syndrome' with slow infusion of vancomycin. New England Journal of Medicine, 313, 756-757.
29. Healy DP, Sahai JV, Fuller SH, Polk RE (1990) Vancomycin-induced histamine release and 'red man syndrome': comparison of 1- and 2-hour infusions. Antimicrobial Agents and Chemotherapy, 34, 550-554.
30. Katzung BG (1998) Basic and clinical pharmacology. Stamford, CT: Appleton & Lange.
31. Ena J, Dick RW, Jones RN, Wenzel RP (1993) The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study. JAMA, 269, 598-602.
32. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH (1990) Nephrotoxicity of vancomycin, alone and with an aminoglycoside. Journal of Antimicrobial Chemotherapy, 25, 679-687.
33. Cunha BA (1995) Vancomycin. Medical Clinics of North America, 79, 817-831.
34. Donald FB (2001) Acute renal failure. In: Young LY, Koda-Kimble MA, eds. Applied therapeutics. Applied Therapeutics Inc, Section 29, 14.